Table 2.
Clinical characteristics and demographics of people who complete the survey.
| Parameter | No, N = 458 a | Yes, N = 492 a |
|---|---|---|
| Age (years) | 28 (25, 33) | 27 (23, 34) |
| Weight (kg) | 60 (55, 67) | 61 (55, 70) |
| Height (m) | 1.62 (1.58, 1.65) | 1.62 (1.58, 1.67) |
| BMI | 22.9 (21.1, 24.9) | 23.4 (21.1, 26.3) |
| BMI category | ||
| Low weight (BMI < 18) | 13 (2.8%) | 20 (4.1%) |
| Normal | 335 (73%) | 307 (62%) |
| Obesity (BMI > 30) | 31 (6.8%) | 56 (11%) |
| Overweight (BMI >25 and <29.9) | 79 (17%) | 109 (22%) |
| Continent | ||
| North America | 14 (3.1%) | 37 (7.5%) |
| South America | 427 (93%) | 422 (86%) |
| Australia | 0 (0%) | 1 (0.2%) |
| Europe | 17 (3.7%) | 32 (6.5%) |
| Planning | ||
| No | 82 (18%) | 119 (24%) |
| Yes | 376 (82%) | 373 (76%) |
| Contraceptive method | ||
| Periodic abstinence | 1 (0.2%) | 5 (1.0%) |
| Combined vaginal ring | 10 (2.2%) | 2 (0.4%) |
| Combined injectable contraceptives | 12 (2.6%) | 19 (3.9%) |
| Combined oral contraceptives (OCs) | 150 (33%) | 94 (19%) |
| Progestin-only oral contraceptives | 5 (1.1%) | 12 (2.4%) |
| Condom | 96 (21%) | 143 (29%) |
| Intrauterine devices | 43 (9.4%) | 33 (6.7%) |
| Progestin-only implants | 25 (5.5%) | 25 (5.1%) |
| Tubal ligation | 21 (4.6%) | 29 (5.9%) |
| Symptothermal method | 2 (0.4%) | 1 (0.2%) |
| I don’t use contraceptive methods | 82 (18%) | 119 (24%) |
| Combined contraceptive patch | 0 (0%) | 1 (0.2%) |
| Vasectomy | 11 (2.4%) | 9 (1.8%) |
| Pregnancy | ||
| No | 453 (99%) | 486 (99%) |
| Yes | 5 (1.1%) | 6 (1.2%) |
| Pre-COVID-19 vaccination menstruation frequency | ||
| Amenorrhea | 25 (5.5%) | 7 (1.4%) |
| Infrequent | 29 (6.3%) | 44 (8.9%) |
| Normal | 387 (84%) | 417 (85%) |
| Frequent | 17 (3.7%) | 24 (4.9%) |
| Pre-COVID-19 vaccination menstruation regularity | ||
| Amenorrhea | 21 (4.6%) | 4 (0.8%) |
| Irregular | 66 (14%) | 76 (15%) |
| Regular | 371 (81%) | 412 (84%) |
| Pre-COVID-19 vaccination menstruation duration | ||
| Amenorrhea | 19 (4.1%) | 4 (0.8%) |
| Normal | 412 (90%) | 449 (91%) |
| Prolonged | 27 (5.9%) | 39 (7.9%) |
| Pre-COVID-19 vaccination menstrual volume | ||
| Amenorrhea | 14 (3.1%) | 5 (1.0%) |
| Light volume | 40 (8.7%) | 37 (7.5%) |
| Normal | 328 (72%) | 335 (68%) |
| Heavy volume | 76 (17%) | 115 (23%) |
| Comorbidities | ||
| Anorexy | 2 (0.4%) | 1 (0.2%) |
| Bulimia | 1 (0.2%) | 1 (0.2%) |
| Polycystic ovary syndrome | 56 (12%) | 63 (13%) |
| None of the above | 399 (87%) | 427 (87%) |
| Weight loss | ||
| No | 406 (89%) | 428 (87%) |
| Yes | 52 (11%) | 64 (13%) |
| High performance athlete | ||
| No | 438 (96%) | 482 (98%) |
| Yes | 20 (4.4%) | 10 (2.0%) |
| Vaccine | ||
| AstraZeneca | 22 (4.8%) | 35 (7.1%) |
| Janssen-Johnson & Johnson | 61 (13%) | 88 (18%) |
| Modern | 47 (10%) | 70 (14%) |
| Others | 9 (2.0%) | 33 (6.7%) |
| Pfizer-BioNTech1 | 256 (56%) | 158 (32%) |
| Sinovac | 63 (14%) | 108 (22%) |
| Complete scheme | ||
| No | 75 (16%) | 130 (26%) |
| Yes | 383 (84%) | 362 (74%) |
| Post-vaccination menstrual frequency | ||
| Amenorrhea | 5 (1.1%) | 48 (9.8%) |
| Infrequent | 2 (0.4%) | 128 (26%) |
| Normal | 449 (98%) | 199 (40%) |
| Frequent | 2 (0.4%) | 117 (24%) |
| Post-vaccination menstrual regularity | ||
| Amenorrhea | 5 (1.1%) | 36 (7.3%) |
| Irregular | 4 (0.9%) | 226 (46%) |
| Normal or regular | 449 (98%) | 230 (47%) |
| Post-vaccination menstrual duration | ||
| Amenorrhea | 5 (1.1%) | 50 (10.1%) |
| Normal | 451 (98%) | 284 (58%) |
| Prolonged | 2 (0.4%) | 158 (32%) |
| Post-vaccination menstrual volume | ||
| Amenorrhea | 6 (1.3%) | 39 (7.9%) |
| Light volume | 4 (0.9%) | 105 (21%) |
| Normal | 444 (97%) | 127 (26%) |
| Heavy volume | 4 (0.9%) | 221 (45%) |
| Change in quality of life | ||
| No | 438 (96%) | 214 (43%) |
| Yes | 20 (4.4%) | 278 (57%) |
BMI: Body Mass Index; IQR: interquartile range.
a
Median (IQR); No. (%).